Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases

International Journal of Urology

Volumn 14, Issue 9, 2007, Pages 828-832

  Soga, Norihito ^a   Onishi, Takehisa ^a   Arima, Kiminobu ^a   Sugimura, Yoshiki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Paclitaxel Carboplatin (Pca); Platinum resistant urothelial cancer; Second line chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; METHOTREXATE; PACLITAXEL; PLATINUM COMPLEX; VINBLASTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER DYSFUNCTION; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PELVIS TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; URETER TUMOR; UROGENITAL TRACT CANCER; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PROSPECTIVE STUDIES; QUALITY OF LIFE; SALVAGE THERAPY; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 34548171153     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01831.x     Document Type: Article

References (18)

1. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 1997 15:2564 9.
2. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005 23:4602 8.
3. Kattan J, Culine S, Theodore C, Droz JP. Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer. Ann. Oncol. 1993 4:793 4.
4. Rosenberg JE, Caroll PR, Small FJ. Update on chemotherapy for advanced bladder cancer. J. Urol. 2005 174:14 20.
5. Sweeney CJ, Williams SD, Finch DE et al. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 1999 86:514 18.
6. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J. Urol. 1995 154:1719 22.
7. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001 92:2993 8.
8. Pycha A, Grbovic M, Posch B et al. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urology 1999 53:510 15.
9. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004 100:1639 45.
10. Vaishampayan UN, Faulkner JR, Small EJ et al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 2005 104:1627 32.
11. Meluch AA, Greco FA, Burris HA 3rd et al. Paclitaxel and gemcitabine. J. Clin. Oncol. 2001 19:3018 24.
12. Kramer JA, Curran D, Piccart M et al. Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur. J. Cancer 2000 36:1488 97.
13. Pectasides D, Aravantinos G, Kalofonos H et al. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 2001 12:1417 22.
14. Krege S, Rembrink V, Borgermann C, Otto T, Rubben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J. Urol. 2001 165:67 71.
15. Pagliaro LC, Millikan RE, Tu SM et al. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J. Clin. Oncol. 2002 20:2965 70.
16. Fechner G, Siener R, Reimann M, Kobalz L, Albers P, German Association of Urologic Oncology (Auo) Bladder Cancer Study Group. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma. Int. J. Clin. Pract. 2005 60:27 31.
17. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol. 2002 20:937.
18. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 1995 13:1584 8.